Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
Technology appraisal guidance
Reference number: TA1115
Published:
Following further consideration of the scheduling of vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy, this topic has now been rescheduled. The committee meeting will now be held on 9 September 2025.